The Resource Cancer drug discovery : science and history, Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim

Cancer drug discovery : science and history, Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim

Label
Cancer drug discovery : science and history
Title
Cancer drug discovery
Title remainder
science and history
Statement of responsibility
Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim
Contributor
Subject
Genre
Language
eng
Summary
This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer
Cataloging source
EBLCP
Dewey number
  • 615.7/98
  • 610
Index
no index present
LC call number
RS431.A64
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
  • Kim, Kyu-Won
  • Roh, Jae Kyung
  • Wee, Hee-Jun
  • Giang Quân
http://library.link/vocab/subjectName
  • Antineoplastic agents
  • Cancer
  • HEALTH & FITNESS
  • HEALTH & FITNESS
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • MEDICAL
  • Antineoplastic agents
  • Cancer
  • Biomedicine
  • Cancer Research
  • Pharmacy
  • History of Medicine
Label
Cancer drug discovery : science and history, Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-94-024-0844-7
Instantiates
Publication
Note
6.1.5.1 Etoposide and€Teniposide
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Part I.A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part II. Cancer Drug Discovery -- Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part III. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs
  • Preface; Contents; Contributors; Part I: A Scientific Overview on Cancer; Chapter 1: Advancements in€Life Sciences and€Characteristic Features of€Cancer Cells; 1.1 Characteristics of€Cancer Cells; 1.2 Characteristic Interactions of€Cancer Cells with€Neighboring Cells and€the€Tumor Microenvironment; 1.2.1 Stromal Cells; 1.2.2 Angiogenesis; 1.2.3 Metastasis of€Malignant Cancer; 1.2.4 Avoidance of€Immune Surveillance; 1.2.5 Tumor-Promoting Inflammatory Responses; References; Chapter 2: Advancement of€the€Science and€History of€Cancer and€Anticancer Drugs; References
  • Part II: Cancer Drug Discovery: Types and HistoryChapter 3: Chronology of€Anticancer Drug Development; 3.1 A Historical Background of€Cancer Chemotherapy; 3.2 Development of€the€Anticancer Drug Screening Systems; 3.2.1 Transplantable Tumor Models in€Animals; 3.2.2 Chemical Tumor Induction and€Anticancer Drug Screening Using Inbred Mice; 3.2.3 Solid Tumor Animal Models and€Xenograft Screening Methods; 3.2.4 Anticancer Drug Screening Methods Based on€Human Cancer Cell Lines; 3.2.5 Mechanism-Based Anticancer Agent Screening Method; 3.3 Chronology of€the€Anticancer Drug Development
  • 3.4 Clinical Application of€Anticancer DrugsReferences; Chapter 4: Alkylating Anticancer Drugs; 4.1 Classical Alkylating Drugs; 4.1.1 Bis Amine/Nitrogen Mustards; 4.1.1.1 Mechlorethamine (Mustine); 4.1.1.2 Chlorambucil; 4.1.1.3 Melphalan; 4.1.1.4 Cyclophosphamide; 4.1.1.5 Ifosfamide; 4.1.1.6 Estramustine; 4.1.1.7 Bendamustine; 4.1.2 Alkyl Sulfonate: Busulfan; 4.1.3 Aziridines (Ethylenimines); 4.1.3.1 ThioTEPA; 4.1.3.2 Mitomycin C; 4.1.4 Nitrosoureas; 4.1.4.1 BCNU (Carmustine); 4.1.4.2 CCNU (Lomustine); 4.1.4.3 Streptozotocin (STZ); 4.2 Nonclassical Alkylating Drugs
  • 4.2.1 Hydrazine: Procarbazine4.2.2 Triazenes; 4.2.2.1 Dacarbazine; 4.2.2.2 Temozolomide; 4.2.3 Altretamines; 4.3 Alkylating-Like Agents: Platinum Compounds; 4.3.1 Cisplatin; 4.3.2 Carboplatin; 4.3.3 Oxaliplatin; References; Chapter 5: Antimetabolic Anticancer Drugs; 5.1 Folic Acid Derivatives; 5.1.1 Methotrexate; 5.1.2 Pemetrexed; 5.1.3 Pralatrexate; 5.2 Purine Analogs; 5.2.1 6-Mercaptopurine and€6-Thioguanine; 5.2.2 Fludarabine; 5.2.3 Pentostatin (22 deoxycoformycin); 5.2.4 Cladribine; 5.2.5 Clofarabine; 5.2.6 Nelarabine; 5.3 Pyrimidine Analogs; 5.3.1 Fluoropyrimidines
  • 5.3.1.1 5-Fluorouracil (5-FU) and€5-Fluorodeoxyuridine Monophosphate (FdUMP)5.3.1.2 Capecitabine; 5.3.2 Deoxycytidine; 5.3.2.1 Cytarabine (Cytosine Arabinoside, ara-C); 5.3.2.2 Gemcitabine (22 22 difluoro-22 deoxycytidine, dFdC); References; Chapter 6: Natural Product Anticancer Drugs; 6.1 Plant-Derived Anticancer Drugs; 6.1.1 Vinca Alkaloids; 6.1.1.1 Vinblastine and€Vincristine; 6.1.1.2 Vinorelbine; 6.1.2 Macrolide: Eribulin; 6.1.3 Taxane; 6.1.3.1 Paclitaxel (Taxol); 6.1.3.2 Docetaxel; 6.1.3.3 Cabazitaxel; 6.1.4 Ixabepilone; 6.1.5 Podophyllotoxins: Topoisomerase II Inhibitors
Dimensions
unknown
Extent
1 online resource (286 pages)
File format
unknown
Form of item
online
Isbn
9789402408423
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
SpringerLink
Other control number
10.1007/978-94-024-0844-7
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)963587907
  • (OCoLC)ocn963587907
Label
Cancer drug discovery : science and history, Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim
Link
https://ezproxy.lib.ou.edu/login?url=http://link.springer.com/10.1007/978-94-024-0844-7
Publication
Note
6.1.5.1 Etoposide and€Teniposide
Antecedent source
unknown
Bibliography note
Includes bibliographical references
Carrier category
online resource
Carrier category code
  • cr
Carrier MARC source
rdacarrier
Color
multicolored
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
  • Part I.A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part II. Cancer Drug Discovery -- Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part III. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs
  • Preface; Contents; Contributors; Part I: A Scientific Overview on Cancer; Chapter 1: Advancements in€Life Sciences and€Characteristic Features of€Cancer Cells; 1.1 Characteristics of€Cancer Cells; 1.2 Characteristic Interactions of€Cancer Cells with€Neighboring Cells and€the€Tumor Microenvironment; 1.2.1 Stromal Cells; 1.2.2 Angiogenesis; 1.2.3 Metastasis of€Malignant Cancer; 1.2.4 Avoidance of€Immune Surveillance; 1.2.5 Tumor-Promoting Inflammatory Responses; References; Chapter 2: Advancement of€the€Science and€History of€Cancer and€Anticancer Drugs; References
  • Part II: Cancer Drug Discovery: Types and HistoryChapter 3: Chronology of€Anticancer Drug Development; 3.1 A Historical Background of€Cancer Chemotherapy; 3.2 Development of€the€Anticancer Drug Screening Systems; 3.2.1 Transplantable Tumor Models in€Animals; 3.2.2 Chemical Tumor Induction and€Anticancer Drug Screening Using Inbred Mice; 3.2.3 Solid Tumor Animal Models and€Xenograft Screening Methods; 3.2.4 Anticancer Drug Screening Methods Based on€Human Cancer Cell Lines; 3.2.5 Mechanism-Based Anticancer Agent Screening Method; 3.3 Chronology of€the€Anticancer Drug Development
  • 3.4 Clinical Application of€Anticancer DrugsReferences; Chapter 4: Alkylating Anticancer Drugs; 4.1 Classical Alkylating Drugs; 4.1.1 Bis Amine/Nitrogen Mustards; 4.1.1.1 Mechlorethamine (Mustine); 4.1.1.2 Chlorambucil; 4.1.1.3 Melphalan; 4.1.1.4 Cyclophosphamide; 4.1.1.5 Ifosfamide; 4.1.1.6 Estramustine; 4.1.1.7 Bendamustine; 4.1.2 Alkyl Sulfonate: Busulfan; 4.1.3 Aziridines (Ethylenimines); 4.1.3.1 ThioTEPA; 4.1.3.2 Mitomycin C; 4.1.4 Nitrosoureas; 4.1.4.1 BCNU (Carmustine); 4.1.4.2 CCNU (Lomustine); 4.1.4.3 Streptozotocin (STZ); 4.2 Nonclassical Alkylating Drugs
  • 4.2.1 Hydrazine: Procarbazine4.2.2 Triazenes; 4.2.2.1 Dacarbazine; 4.2.2.2 Temozolomide; 4.2.3 Altretamines; 4.3 Alkylating-Like Agents: Platinum Compounds; 4.3.1 Cisplatin; 4.3.2 Carboplatin; 4.3.3 Oxaliplatin; References; Chapter 5: Antimetabolic Anticancer Drugs; 5.1 Folic Acid Derivatives; 5.1.1 Methotrexate; 5.1.2 Pemetrexed; 5.1.3 Pralatrexate; 5.2 Purine Analogs; 5.2.1 6-Mercaptopurine and€6-Thioguanine; 5.2.2 Fludarabine; 5.2.3 Pentostatin (22 deoxycoformycin); 5.2.4 Cladribine; 5.2.5 Clofarabine; 5.2.6 Nelarabine; 5.3 Pyrimidine Analogs; 5.3.1 Fluoropyrimidines
  • 5.3.1.1 5-Fluorouracil (5-FU) and€5-Fluorodeoxyuridine Monophosphate (FdUMP)5.3.1.2 Capecitabine; 5.3.2 Deoxycytidine; 5.3.2.1 Cytarabine (Cytosine Arabinoside, ara-C); 5.3.2.2 Gemcitabine (22 22 difluoro-22 deoxycytidine, dFdC); References; Chapter 6: Natural Product Anticancer Drugs; 6.1 Plant-Derived Anticancer Drugs; 6.1.1 Vinca Alkaloids; 6.1.1.1 Vinblastine and€Vincristine; 6.1.1.2 Vinorelbine; 6.1.2 Macrolide: Eribulin; 6.1.3 Taxane; 6.1.3.1 Paclitaxel (Taxol); 6.1.3.2 Docetaxel; 6.1.3.3 Cabazitaxel; 6.1.4 Ixabepilone; 6.1.5 Podophyllotoxins: Topoisomerase II Inhibitors
Dimensions
unknown
Extent
1 online resource (286 pages)
File format
unknown
Form of item
online
Isbn
9789402408423
Level of compression
unknown
Media category
computer
Media MARC source
rdamedia
Media type code
  • c
Note
SpringerLink
Other control number
10.1007/978-94-024-0844-7
Quality assurance targets
not applicable
Reformatting quality
unknown
Sound
unknown sound
Specific material designation
remote
System control number
  • (OCoLC)963587907
  • (OCoLC)ocn963587907

Library Locations

  • Architecture LibraryBorrow it
    Gould Hall 830 Van Vleet Oval Rm. 105, Norman, OK, 73019, US
    35.205706 -97.445050
  • Bizzell Memorial LibraryBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Boorstin CollectionBorrow it
    401 W. Brooks St., Norman, OK, 73019, US
    35.207487 -97.447906
  • Chinese Literature Translation ArchiveBorrow it
    401 W. Brooks St., RM 414, Norman, OK, 73019, US
    35.207487 -97.447906
  • Engineering LibraryBorrow it
    Felgar Hall 865 Asp Avenue, Rm. 222, Norman, OK, 73019, US
    35.205706 -97.445050
  • Fine Arts LibraryBorrow it
    Catlett Music Center 500 West Boyd Street, Rm. 20, Norman, OK, 73019, US
    35.210371 -97.448244
  • Harry W. Bass Business History CollectionBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • History of Science CollectionsBorrow it
    401 W. Brooks St., Rm. 521NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • John and Mary Nichols Rare Books and Special CollectionsBorrow it
    401 W. Brooks St., Rm. 509NW, Norman, OK, 73019, US
    35.207487 -97.447906
  • Library Service CenterBorrow it
    2601 Technology Place, Norman, OK, 73019, US
    35.185561 -97.398361
  • Price College Digital LibraryBorrow it
    Adams Hall 102 307 West Brooks St., Norman, OK, 73019, US
    35.210371 -97.448244
  • Western History CollectionsBorrow it
    Monnet Hall 630 Parrington Oval, Rm. 300, Norman, OK, 73019, US
    35.209584 -97.445414
Processing Feedback ...